Eli Lilly Stock (LLY) Implodes On Failed Alzheimer’s Data

Eli Lilly And Co (NYSE: LLY) Eli Lilly stock is getting hammered in pre-market trading on Wednesday, down by over 15% (9:10EST) on news that its drug to treat Alzheimer’s patients, solanezumab, missed the study’s main goal when patients that were taking the drug did not experience a meaningful decline in the loss of cognitive … Read more

Biotech Stock News (AVXL) (BIIB) (LLY) (SPHS) (KBIO)

Anavex Life Sciences (NASDAQ:AVXL) On November 9, 2015 Anavex reported positive phase 2a results for the trial treating patients with Alzheimer’s. This trial tested two clinical endpoints. The first clinical endpoint was testing for safety as it is customary with all phase 2a trials. The second endpoint was looking for preliminary clinical efficacy. In terms … Read more

Biotech Stock News (LXRX) (BIOC) (LLY) (AMGN) (AQXP)

Lexicon Pharmaceuticals (NASDAQ:LXRX)  On August 3, 2015 shares of Lexicon Pharmaceuticals were up 61% after the company posted positive phase 3 Results in Patients with Carcinoid Syndrome. Carcinoid Syndrome occurs when a carcinoid tumor advances to a later stage. Typically this disease targets the lining of the lungs or stomach of the patient and has … Read more

Biotech Stock News (BIIB) (LLY) (AVXL) (ITEK) (XOMA)

Biogen (NASDAQ:BIIB) On July 22, 2015 shares of Biogen fell about 4% after reporting mixed results for its Alzheimer’s drug known as aducanumab. This phase 1b trial was known as the “PRIME” trial and patients were randomized into two different dosing groups. One group of patients either took 1 mg, 3 mg , 6 mg … Read more